Nocturia is a relatively common urological problem and involves waking up more than twice during the night to void the bladder. Nocturia tends to be caused by other underlying diseases and processes, such as polyuria, Benign Prostatic Hyperplasia (BPH) or bladder storage disorders. This report provides the current prevalent population for Nocturia across 8 Major Markets (USA, France, Germany, Italy, Spain, UK, Brazil and Japan) split by gender and 5-year age cohort. Along with the current prevalence, the report provides an overview of the types, occlusion locations and the prevalence of associated disorders of Nocturia. The report also contains a disease overview of the risk factors, disease diagnosis and prognosis along with specific variations by geography and ethnicity.

Providing a value-added level of insight from the analysis team at Black Swan, several of the main symptoms and co-morbidities of Nocturia have been quantified and presented alongside the overall prevalence figures. These sub-populations within the main disease are also included at a country level across the 10-year forecast snapshot.

Main symptoms and co-morbidities for Nocturia include:

  • Diabetes
  • Hypertension
  • Multiple sclerosis
  • Urinary Incontinence
  • Benign Prostatic Hyperplasia
  • Chronic Heart Failure
  • Chronic kidney disease
  • Overactive bladder
  • Alcohol consumption

This report is built using data and information sourced from the proprietary Epiomic patient segmentation database. To generate accurate patient population estimates, the Epiomic database utilises a combination of several world class sources that deliver the most up to date information form patient registries, clinical trials and epidemiology studies. All of the sources used to generate the data and analysis have been identified in the report.

Reason to buy

  • Able to quantify patient populations in global Nocturia’s market to target the development of future products, pricing strategies and launch plans.
  • Gain further insight into the prevalence of the subdivided types of Nocturia and identify patient segments with high potential.
  • Delivery of more accurate information for clinical trials in study sizing and realistic patient recruitment for various countries.
  • Provide a level of understanding on the impact from specific co-morbid conditions on Nocturia’s prevalent population.
  • Identify sub-populations within Nocturia which require treatment.
  • Gain an understanding of the specific markets that have the largest number of Nocturia patients.